Atypical Presentation of Chronic Myelogenous Leukemia
نویسندگان
چکیده
منابع مشابه
Atypical Presentation of Chronic Myelogenous Leukemia
Chronic myelogenous leukemia (CML) is a clonal myeloproliferative disorder characterized by the presence of the Philadelphia chromosome, t(9;22), which is a constitutively active tyrosine kinase that causes excessive proliferation and differentiation of myeloid cells in the bone marrow. Most patients are either asymptomatic or present with fatigue, abdominal fullness, and splenomegaly. This is ...
متن کاملFunction of Neutrophils in Different Phases of Chronic Myelogenous Leukemia
In chronic myelogenous leukemia (CML), the mature granulocytes originate from a stem cell line harboring an abnormal chromosome, therefore it is possible that metabolic-functional abnormalities occur in the morphologically mature cells. In the present study, the phagocytic activity including intracellular killing, nitro blue tetrazolium (NBT) reduction, and phagocytosis were studied in 37 CML p...
متن کاملVisual loss as initial presentation of chronic myelogenous leukemia.
A previously healthy 17-year old girl presented with sudden visual loss in both eyes. Visual acuity on the right eye was 0.3 and on the left eye 0.1. Fundoscopic examination showed bilateral optic disc edema, retinal venous tortuousity and dilatation, retinal blot and flame-shaped hemorrhages, Roth spots and on the left eye dark blot preretinal hemorrhage covering the fovea. Laboratory evaluati...
متن کاملFlow Cytometry in Chronic Myelogenous Leukemia Blast Crisis
Background: Chronic myelogenous leukemia (CML) is a myeloproliferative disorder due to BCR-ABL1 translocation. Patients showing transformation into blast crisis (BC) have poorer treatment response and prognosis. Methods: A retrospective study was conducted in the department of Pathology, Maulana Azad Medical College, New Delhi, India, over a time period of 5 years (2014-2019) to evaluate the ...
متن کاملChronic myelogenous leukemia.
The treatment recommendations for chronic myelogenous leukemia (CML) are evolving rapidly. In the past year, pegylated interferon and STI571 (Gleevec, imatinib mesylate), a Bcr-Abl tyrosine kinase inhibitor, have become commercially available and non-myeloablative stem cell transplants continue to be refined. Clinicians and patients face a bewildering array of treatment options for CML. In this...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cureus
سال: 2017
ISSN: 2168-8184
DOI: 10.7759/cureus.1280